{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:07:26Z","timestamp":1777378046313,"version":"3.51.4"},"reference-count":12,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T00:00:00Z","timestamp":1506124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Medtronic, Santa Rosa, California"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the safety and efficacy of the novel Resolute (R\u2010) Onyx drug\u2010eluting stent (DES).<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>The R\u2010Onyx DES consists of a composite wire with an outer shell of cobalt chromium alloy and a platinum\u2010iridium inner core to enhance radiopacity, with thinner, swaged struts and modified stent geometry compared with the predicate Resolute DES, resulting in a slightly lower total drug load in most sizes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a prospective, single\u2010arm non\u2010inferiority trial compared with a historical control. Patients with stable angina\/ischemia and up to 2 <jats:italic>de novo<\/jats:italic> target lesions \u226435 mm long with reference vessel diameter (RVD) of 2.25\u20134.2 mm were enrolled. The primary endpoint was late lumen loss at 8\u2010month follow\u2010up. Propensity\u2010score adjusted outcomes from the single\u2010arm RESOLUTE\u2010US trial served as the control.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy\u2010five patients (85 lesions) were enrolled. Mean patient age was 66\u2009\u00b1\u20099 years, 73% were male, and 32% had diabetes. Mean lesion length was 14.28\u2009\u00b1\u20096.68 mm, mean RVD was 2.57\u2009\u00b1\u20090.48 mm, and 86% of lesions were class B2\/C. In\u2010stent late lumen loss at 8 months was 0.24\u2009\u00b1\u20090.39 mm with R\u2010Onyx DES compared with 0.36\u2009\u00b1\u20090.52 mm with Resolute DES (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001 for noninferiority, <jats:italic>P<\/jats:italic>\u2009=\u20090.029 for superiority). At 8 months, clinically driven target lesion revascularization occurred in 3 patients (4.0%) and target lesion failure occurred in 5 patients (6.7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In\u2010stent late lumen loss is non\u2010inferior, and appears to be superior, with the thin\u2010strut novel composite wire R\u2010Onyx DES compared with Resolute DES. Continued evolution of stent design can improve angiographic outcomes in complex lesions, even in the current era of next\u2010generation DES.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ccd.27322","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T07:08:45Z","timestamp":1506150525000},"page":"253-259","source":"Crossref","is-referenced-by-count":19,"title":["Safety and efficacy of the next generation Resolute Onyx zotarolimus\u2010eluting stent: Primary outcome of the RESOLUTE ONYX core trial"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7892-2430","authenticated-orcid":false,"given":"Matthew J.","family":"Price","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Diseases Scripps Clinic La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Shlofmitz","sequence":"additional","affiliation":[{"name":"Department of Cardiology Saint Francis Hospital Roslyn New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas J.","family":"Spriggs","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology Morton Plant Hospital Clearwater Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Haldis","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology Sanford Health Fargo North Dakota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Myers","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology Tristar Centennial Medical Center Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Popma Almonacid","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Core Laboratory Beth Israel Deaconess Medical Center Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Maehara","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Foundation  New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Dauler","sequence":"additional","affiliation":[{"name":"Coronary Clinical Department Medtronic Santa Rosa California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[{"name":"Coronary Clinical Department Medtronic Santa Rosa California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"Department of Cardiology Mount Sinai Medical Center  New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,9,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004130"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV7I10A189"},{"key":"e_1_2_9_4_1","first-page":"630","article-title":"Three\u2010year outcomes of percutaneous coronary intervention with next\u2010generation zotarolimus\u2010eluting stents for de novo coronary bifurcation lesions","volume":"26","author":"Ferenc M","year":"2014","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62127-9"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01107.2004"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.07.028"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.23267"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.03.005"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31823a5596"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.23.2816"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.02.053"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.002372"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.27322","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.27322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T12:46:20Z","timestamp":1694954780000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.27322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,23]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1002\/ccd.27322"],"URL":"https:\/\/doi.org\/10.1002\/ccd.27322","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,23]]}}}